SEKISUI XENOTECH

Accelerating the Path to IND with Strategic Science, Quality Products and Global Expertise

At Sekisui XenoTech, we pride ourselves on an outstanding record of client retention, and are committed to continually improving our products and services to meet the industry's changing needs.

About XenoTech

XenoTech was founded by Dr. Andrew Parkinson in 1994 as a Contract Research Organization serving clients with our unparalleled experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes. Since then, we have expanded our capabilities to accommodate the evolution of drug development strategies.

XenoTech conducts a variety of *in vitro* pre-clinical studies that meet or exceed the current regulatory guidances to assess the victim and perpetrator potential of drug candidates, which can be conducted as either non-GLP or GLP-compliant studies.

The additional experience of our parent company, Sekisui Medical Company, and other specialized partners allows us to deliver a variety of pre-clinical drug development studies featuring a growing selection of validated assays and novel test systems.

Our experience allows us a unique position of having seen thousands of compounds under late-stage development. We can advise our customers about their compound's victim / perpetrator potential and make recommendations for further studies on each compound. Our goal is to deliver the highest quality information about your compound to support a successful IND submission.

Facilities

XenoTech's products and services are managed from our headquarters in Kansas City, KS, USA. This cutting-edge, restricted access facility was custom-designed to support our contract services, research and development, product preparation, storage and distribution.

Products

We have one of the most extensive selections of tissue-derived products for *in vitro* drug metabolism-related research. Our standard products feature both subcellular fractions and hepatocytes from toxicologically-relevant species such as human, monkey, minipig, dog, guinea pig, rat, hamster and mouse.

Our selection ranges from large donor pools to specialty items for specific investigations, such as genotyped microsomes from individuals having polymorphically-expressed enzymes, custom preparations from non-standard species or from human donors with distinct demographics. Whatever your *in vitro* research needs, XenoTech can help.

Services

- Protein Binding
- Radio-labeled Compound Synthesis
- Quantitative whole-body autoradiography (QWBA)
- Enzyme Inhibition
- Enzyme Induction
- Reaction Phenotyping (Enzyme Mapping)
- Species Comparison
- Metabolic Stability
- Metabolite Characterization and Identification
- Toxicity in Primary Cultures of Human and Animal Hepatocytes
- Transporter Studies
- In Vivo Pharmacokinetic Studies
- Radiolabeled Compound Synthesis
- Screening Studies
- Radioreceptor Assays
- Discovery Screening (XenoGesis)

About Sekisui

Drug Development Solutions Center of Sekisui Medical Co., Ltd. began as the Tokai Research Institute of Daiichi Pure Chemicals Co., Ltd in 1965 with the objective of contributing to the advancement and development of academic research through its radioisotope business. That business has grown and expanded into a broad range of pharmaceutical development research capabilities, from optimization of lead compounds to post-marketing surveillance of drugs.

Our campus in Tokai, Japan features almost 150,000 ft^2, consisting of corporate & administrative offices and research laboratories on 8.42 acres. Laboratories include two clean rooms for cell culture, an animal care facility, and a large variety of instrumentation to support both cold and hot compound investigations (including radiolabeling services) for *in vivo* and *in vitro* ADME/Tox studies. We have over 20 years of experience in QWBA, and are one of the most trusted contract service providers in Japan.

We have continually responded to the changing requirements in the process of drug development, establishing a Quality Assurance System for the implementation of GLP studies, and actively advanced the introduction of new study systems such as those used for evaluating drug efficacy, toxicity and pharmacokinetics in humans to predict any potential risk to humans as early as possible.